XOMA Royalty Corporation (XOMAP) Stock Analysis & Investment Frameworks
XOMA Royalty Corporation (XOMAP) stock analysis on Invetso. Review XOMA Royalty Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
XOMA Royalty Corporation Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
XOMA Royalty Corporation Key Financial Metrics
- Market Cap: $301.34M
- Revenue: $52.15M
- P/E Ratio: 9.5
- ROE: 32.41%
- ROIC: 1.94%
- Dividend Yield: 8.63%
About XOMA Royalty Corporation
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Royalty Corporation Investment Frameworks
Invetso analyzes XOMA Royalty Corporation (XOMAP) across the following frameworks:
- XOMA Royalty Corporation 10Y Growth Potential
- XOMA Royalty Corporation Scenario Analysis
- XOMA Royalty Corporation Risks & Opportunities
- XOMA Royalty Corporation Economic Moat
- XOMA Royalty Corporation Business Model
- XOMA Royalty Corporation Management
- XOMA Royalty Corporation SWOT Analysis
- XOMA Royalty Corporation Porter's 5 Forces
- XOMA Royalty Corporation PESTLE Analysis
- XOMA Royalty Corporation ESG Analysis